- Titre
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
- Créateurs - sans rôle
- David R. Spigel - Sarah CannonCorinne Faivre-Finn - The University of Manchester and The Christie NHS Foundation Trust, Manchester, United KingdomJhanelle E. Gray - Moffitt Cancer CenterDavid Vicente - Hospital Universitario Virgen Macarena, Seville, SpainDavid Planchard - Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, FranceLuis Paz-Ares - Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, SpainJohan F. Vansteenkiste - University Hospitals KU Leuven, Leuven, BelgiumMarina C. Garassino - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology/Oncology, The University of Chicago, Chicago, ILRina Hui - Westmead Hospital and the University of Sydney, Sydney, New South Wales, AustraliaXavier Quantin - Institut de Recherche en Cancérologie de MontpellierAndreas Rimner - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NYYi-Long Wu - Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, ChinaMustafa Özgüroğlu - Istanbul University—Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TurkeyKi H. Lee - Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of KoreaTerufumi Kato - Kanagawa Cancer Center, Yokohama, JapanMaike de Wit - Vivantes Klinikum Neukölln, Berlin, GermanyTakayasu Kurata - Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, JapanMartin Reck - Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, GermanyByoung C. Cho - Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of KoreaSuresh Senan - Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the NetherlandsJarushka Naidoo - Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy at John Hopkins University, Baltimore, MDHelen Mann - AstraZeneca, Cambridge, United KingdomMichael Newton - AstraZeneca, Gaithersburg, MDPiruntha Thiyagarajah - AstraZeneca, Cambridge, United KingdomScott J. Antonia - Moffitt Cancer CenterPACIFIC Investigators
- Détails de publication
- Journal of clinical oncology, Vol.40(12), pp.1301-1311
- Nombre de pages
- 11
- Identifiants
- 99141143809311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal of clinical oncology, Vol.40(12), pp.1301-1311
20/04/2022
PMID: 35108059
Indicateurs
1 Consultations de la notice